Ask about this productRelated genes to: CKMM antibody
- Gene:
- CKM NIH gene
- Name:
- creatine kinase, M-type
- Previous symbol:
- CKMM
- Synonyms:
- -
- Chromosome:
- 19q13.32
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2016-02-10
Related products to: CKMM antibody
Related articles to: CKMM antibody
- - Source: PubMed
Publication date: 2026/04/21
Long XinyangLi MingliLi DantongMo Zengnan - Cardiovascular-kidney-metabolic (CKM) syndrome is defined by the pathologic interconnections between obesity, diabetes, chronic kidney disease and cardiovascular disease. An important and underrecognized pathophysiologic factor underlying CKM syndrome is obesity-induced aldosterone excess. This excess aldosterone causes structural and functional alterations in the kidneys, heart and vasculature promoting development of chronic kidney disease, cardiovascular disease and heart failure. Inhibition of aldosterone signalling is a pillar in the treatment approach to CKM syndrome. Pharmacologic options include renin-angiotensin-aldosterone system (RAAS) inhibitors, angiotensin receptor-neprilysin inhibitors and steroidal (such as spironolactone) or non-steroidal (currently only finerenone) mineralocorticoid receptor antagonists. Additionally, aldosterone synthase inhibitors are currently in development. Effective anti-obesity medications such as glucagon-like peptide-1 receptor agonists inhibit aldosterone production due to their effects on adipocytes and in the kidneys. RAAS inhibition is also used to optimize the long-term management of CKM syndrome. Future research should seek to characterize the benefits of combination therapies for aldosterone excess and determine which subgroups of patients most benefit from aldosterone-targeted therapies. - Source: PubMed
Publication date: 2026/04/20
Zeitler EvanKlein Klara RLingvay IldikoPick AnthonyBillings Liana K - Co-existence of multiple cardiovascular-kidney-metabolic (CKM) conditions, such as chronic kidney disease (CKD), type 2 diabetes (T2D), and cardiovascular disease, is common. The interconnected nature of CKM conditions emphasizes the need for an interprofessional approach to patient care. As the prevalence of people with CKM conditions continues to rise in the United States and the burden on the health care system increases, clinical pharmacists are well-positioned to provide support within interprofessional teams and improve patient access to care through delivery of education, assessments and monitoring, and optimal initiation and maintenance of guideline-directed medical therapy (GDMT). - Source: PubMed
St Peter Wendy LNeumiller Joshua JAlicic RadicaChow Sheryl LDowell HadleyDuru O KenrikGee PatrickMathew Roy ONicholas Susanne BRangaswami JananiRoberts Glenda VVaduganathan MuthiahTuttle Katherine R - Cardiovascular-kidney-metabolic (CKM) syndrome represents a progressive disease continuum linking metabolic risk factors with cardiovascular and kidney disease. Patients in early CKM stages (stages 1-2) represent a critical therapeutic window; however, comparative evidence on pharmacologic strategies to prevent progression to advanced CKM stages remains limited. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, has demonstrated superior metabolic efficacy compared with conventional GLP-1 receptor agonists (GLP-1 RAs), but its impact on CKM stage progression in real-world practice is unknown. - Source: PubMed
Publication date: 2026/04/18
Wu Jheng-YanLee Keng-WeiHuang Sheng-ChiChang Hsuan-YuanLin Yu-Min - The cholesterol, high-density lipoprotein, and glucose (CHG) index and stroke risk among individuals with cardiovascular-kidney-metabolic (CKM) syndrome stages 0-3 is unclear. - Source: PubMed
Publication date: 2026/04/18
Lu FangfangYang Fan